Recently, APAC CIOoutlook officially released the list of "Top Pharma and Life Science Technology Company". SBS Genetech stands out from biotech companies all over the world. At the same time, Stephen Lan, the vice president of SBS Genetech, received an exclusive interview for the cover story, which once again proved the high recognition of SBS Genetech by market and industry experts.
As the top professional media in Asia Pacific, APAC CIOoutlook is a unique platform for technology buyers and sellers to come together and share their expertise, with more than 29,000 subscribers from Pharma and Life Science industry. "Top Pharma and Life Science Technology Company" is an important annual list in the Asia Pacific region, which has a wide influence among pharma and life science professionals.
“We believe that by providing researchers with convenient and affordable research products, life sciences can benefit the world better.” Stephen Lan, the vice president of SBS Genetech, said in an interview with APAC CIOoutlook. With almost two decades into its inception, SBS Genetech has witnessed the lows and highs in the industry, while also experiencing the marvels that the life sciences realm has brewed over the years. Backed by this unprecedented expertise and in-depth industry knowledge, the company has been recognized as a high-quality, trusted provider of life sciences research and application services and products.
SBS Genetech now offers a broad portfolio coverage, including DNA/RNA oligonucleotide synthesis, gene synthesis, peptide synthesis, biochemical reagents, PCR-related products, RNA-related products, gene manipulation kits, and more. The uniqueness of SBS Genetech stems from its well-established sales and distribution network widespread over more than 40 countries, and its strategic cooperation with dozens of other competitive suppliers in specific areas, ensuring its heightened product quality and multifaceted pricing advantages.
Under the premise of guaranteeing the cost-performance ratio of products, SBS Genetech will rapidly expand its portfolio along the main business line. The company has already expanded its DNA synthesis services to cover various nucleic acid synthesis services, including siRNA synthesis, miRNA synthesis, and sgRNA synthesis, used for gene editing. “We will accelerate this process to further enhance our competitiveness by covering more scenarios in life sciences research,” concludes Lan.